Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Glofitamab

Glofitamab

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Teclistamab and glofitamab carry higher non-relapse mortality signals than mosunetuzumab in BsAb meta-analysis
Oncology Meta-analysis
Teclistamab and glofitamab carry higher non-relapse mortality signals than mosunetuzumab in BsAb meta-analysis New data reveals safety risks for certain lymphoma and myeloma drugs
This meta-analysis combined a systematic review and meta-analysis with FAERS pharmacovigilance data to estimate non-relapse mortality (NRM) …
New data highlights different safety risks and side effects for three specific drugs used to treat certain types of blood cancers.
Nov 1, 2026
Glofitamab plus selinexor maintenance yields sustained CR in refractory DLBCL case
Anesthesiology & Pain Medicine Sys. Review
Glofitamab plus selinexor maintenance yields sustained CR in refractory DLBCL case New treatment strategy shows promise for hard to treat lymphoma
This case report and literature review describes a 70-year-old man with primary refractory DLBCL harboring TP53 and CD58 mutations who achie…
A new treatment plan using glofitamab and selinexor helped a 70-year-old man with a very aggressive form of lymphoma achieve a lasting respo…
Frontiers Oct 30, 2026